Menu
Search Close

Investors

Advisors

Country of Incorporation :
UK

Main Country of Operation:
UK

Company registered address and number:
John Eccles House 
Robert Robinson Avenue
Oxford Science Park 
Oxford
OX4 4GP
Company registration number: 06564638(England and Wales)

Registrar:
SLC Registrars
Elder House
St George's Business Park
Weybridge
Surrey
KT13 0TS
Telephone +44 (0)1903 706 150 
Fax +44 (0)333 207 6354

Nominated advisor and Broker:
Panmure Gordon and Co
One New Change
London
EC4M 9AF

Auditor:
Champion Accountants LLP
2nd Floor
Refuge House
33-37 Watergate Row
Chester
CH1 2LE

Solicitor:
Cooley (UK) LLP
Dashwood
69 Old Broad Street
London
EC2M 1QS

Webcasts, Interviews and Media Coverage

Scancell in vanguard of immuno-oncology advances, with two technologies that show early promise

The AIM-listed group is at the vanguard of advances in the emerging field of immuno-oncology and is working on two technologies that are showing early promise

Tue, 12 Feb 2019 15:07:00

Scancell lauds another six months of progress

The funds raised in the last year "will allow us to focus on initiating the planned Phase 2 clinical trial for our lead ImmunoBody, SCIB1, and to advance our Moditope products, Modi-1 and Modi-2, towards the clinic".

Thu, 31 Jan 2019 08:41:00

Award shortlist 'a significant scientific endorsement' of Scancell's technology

Cliff Holloway, chief executive of Scancell Holdings Plc (LON:SCLP), tells Proactive London's Andrew Scott the company's received “significant scientific endorsement” of its technology after it and a group of collaborators were shortlisted for a major award.

It teamed up with BioNTech, Genentech and ISA Pharmaceuticals to form Project Blueprint for Cancer Research UK’s Grand Challenge.

The team outlined plans to eradicate established tumours with its unique vaccine, which had Scancell’s Modi-3 treatment at its heart.

Wed, 23 Jan 2019 12:25:00